Stem cell transplantation for aplastic anemia

International Journal of Hematology

Volumn 75, Issue 2, 2002, Pages 141-146

  Georges, George E ^a,b   Storb, Rainer ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antithymocyte globulin; Aplastic anemia; Bone marrow transplantation; Cyclophosphamide; Graft rejection

Indexed keywords

ANIMAL; APLASTIC ANEMIA; BONE MARROW TRANSPLANTATION; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY TEST; HUMAN; IMMUNOLOGY; METHODOLOGY; MORTALITY; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL RATE; CONDITIONING; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN;

ANEMIA, APLASTIC; ANIMALS; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; THYMOCYTE ANTIBODY;

EID: 0036463675     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982018     Document Type: Review

References (56)

1. Lum LG, Seigneuret MC, Doney KC, Storb R. In vitro immunoglobulin production, proliferation, and cell markers before and after antithymocyte globulin therapy in patients with aplastic anemia. Am J Hematol. 1987;26:1-15.
2. Elfenbein GJ, Kallman CH, Tutschka PJ, et al. The immune system in 40 aplastic anemia patients receiving conventional therapy. Blood. 1979;53:652-665.
3. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89:3048-3054.
4. Santos GW, Owens AH Jr. Allogeneic marrow transplants in cyclophosphamide treated mice. Transplant Proc. 1969;1:44-46.
5. Storb R, Epstein RB, Rudolph RH, Thomas ED. Allogeneic canine bone marrow transplantation following cyclophosphamide. Transplantation. 1969;7:378-386.
6. Thomas ED, Buckner CD, Storb R, et al. Aplastic anaemia treated by marrow transplantation. Lancet. 1972;I:284-289.
7. Storb R, Thomas ED, Buckner CD, et al. Allogeneic marrow grafting for treatment of aplastic anemia. Blood. 1974;43:157-180.
8. Storb R, Prentice RL, Thomas ED. Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. N Engl J Med. 1977;296:61-66.
9. van Bekkum DW, Bach F, Bergan JJ, et al. Bone marrow transplantation from histocompatible, allogeneic donors for aplastic anemia. A report from the ACS/NIH bone marrow transplant registry. JAMA. 1976;236:1131-1135.
10. Storb R, Weiden PL, Deeg HJ, et al. Rejection of marrow from DLA-identical canine littermates given transfusions before grafting: antigens involved are expressed on leukocytes and skin epithelial cells but not on platelets and red blood cells. Blood. 1979;54:477-484.
11. Storb R, Prentice RL, Thomas ED, et al. Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia. Br J Haematol. 1983;55:573-585.
12. Deeg HJ, Aprile J, Storb R, et al. Functional dendritic cells are required for transfusion-induced sensitization in canine marrow graft recipients. Blood. 1988;71:1138-1140.
13. Anasetti C, Doney KC, Storb R, et al. Marrow transplantation for severe aplastic anemia: long term outcome in fifty "untransfused" patients. Ann Intern Med. 1986;104:461-466.
14. Storb R, Sanders JE, Pepe M, et al. Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts [letter]. Blood. 1991;78:1144-1145.
15. Bean MA, Storb R, Graham T, et al. Prevention of transfusion-induced sensitization to minor histocompatibility antigens on DLA-identical canine marrow grafts by gamma irradiation of marrow donor blood. Transplantation. 1991;52:956-960.
16. Bean MA, Graham T, Appelbaum FR, et al. Gamma-irradiation of pretransplant blood transfusions from unrelated donors prevents sensitization to minor histocompatibility antigens on dog leukocyte antigen-identical canine marrow grafts. Transplantation. 1994;57:423-426.
17. Bortin MM, Gale RP, Rimm AA, for the Advisory Committee of the International Bone Marrow Transplant Registry. Allogeneic bone marrow transplantation for 144 patients with severe aplastic anemia. JAMA. 1981;245:1132-1139.
18. Gluckman E, Barrett AJ, Arcese W, Devergie A, Degoulet P. Bone marrow transplantation in severe aplastic anemia: a survey of the European Group for Bone Marrow Transplantation (E.G.B.M.T.). Br J Haematol 1981;49:165-173.
19. Storb R, Thomas ED, Appelbaum FR, et al. Marrow transplantation for severe aplastic anemia: the Seattle experience. In: Young NS, Levine AS, Humphries RK, eds. Aplastic Anemia: Stem Cell Biology and Advances in Treatment. New York, NY: Alan R. Liss Inc; 1984:297-313.
20. Deeg HJ, Prentice R, Fritz TE, et al. Increased incidence of malignant tumors in dogs after total body irradiation and marrow transplantation. Int J Radiat Oncol Biol Physiol. 1983;9:1505-1511.
21. Deeg HJ, Socié G, Schoch G, et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87:386-392.
22. Sanders JE, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood. 1996;87:3045-3052.
23. Storb R, Doney KC, Thomas ED, et al. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. Blood. 1982;59:236-246.
24. Storb R, Deeg HJ, Farewell V, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood. 1986;68:119-125.
25. Storb R, Floersheim GL, Weiden PL, et al. Effect of prior blood transfusions on marrow grafts: abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol. 1974;112:1508-1516.
26. Weiden PL, Storb R, Slichter S, Warren RP, Sale GE. Effect of six weekly transfusions on canine marrow grafts: tests for sensitization and abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol. 1976;117:143-150.
27. Storb R, Weiden PL, Sullivan KM, et al. Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. Blood. 1987;70:116-121.
28. Storb R, Etzioni R, Anasetti C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994;84:941-949.
29. Storb R, Blume KG, O'Donnell MR, et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant 2001;7:39-44.
30. Locatelli F, Bruno B, Zecca M, et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood. 2000;96:1690-1697.
31. Niederwieser D, Pepe M, Storb R, Loughran TP Jr, Longton G, for the Seattle Marrow Transplant Team. Improvement in rejection, engraftment rate and survival without increase in graft-versus-host disease by high marrow cell dose in patients transplanted for aplastic anemia. Br J Haematol. 1988;69:23-28.
32. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344:175-181.
33. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729-735.
34. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 1992;80:1838-1845.
35. Storb R, Pepe M, Anasetti C, et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood. 1990;76:1037-1045.
36. Chao NJ, Snyder DS, Jain M, et al. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant. 2000;6:254-261.
37. Champlin RE, Horowitz MM, van Bekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989;73:606-613.
38. Passweg JR, Socié G, Hinterberger W, et al. Bone marrow transplant for severe aplastic anemia: has outcome improved? Blood. 1997;90:858-864.
39. Storb R, Thomas ED, Buckner CD, et al. Allogeneic marrow grafting for treatment of aplastic anemia: a follow-up on long-term survivors. Blood. 1976;48:485-490.
40. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983;98:461-466.
41. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250-259.
42. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, and the Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529-1533.
43. Deeg HJ, Leisenring W, Storb R, et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood. 1998;91:3637-3645.
44. Bunin N, Leahey A, Kamani N, August C. Bone marrow transplantation in pediatric patients with severe aplastic anemia: cyclophosphamide and anti-thymocyte globulin conditioning followed by recombinant human granulocyte-macrophage colony stimulating factor. J Pediatr Hematol Oncol. 1996;18:68-71.
45. Horstmann M, Stockschlaeder M, Kruger W, et al. Cyclophosphamide/ antithymocyte globulin conditioning of patients with severe aplastic anemia for marrow transplantation from HLA-matched siblings: preliminary results. Ann Hematol. 1995;71:77-81.
46. Azuma E, Kojima S, Kato K, et al. Conditioning with cyclophosphamide/ antithymocyte globulin for allogeneic bone marrow transplantation from HLA-matched siblings in children with severe aplastic anemia. Bone Marrow Transplant. 1997;19:1085-1087.
47. Deeg HJ, Seidel K, Casper J, et al. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant. 1999;5:243-252.
48. Hows JM, Yin JL, Marsh J, et al. Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. Blood. 1986;68:1322-1328.
49. Gajewski JL, Chattopadhyay A. Treatment of aplastic anemia with bone marrow transplants from closely matched unrelated donors. In: Champlin RE, Gale RP, eds. New Strategies in Bone Marrow Transplantation. New York, NY: Wiley-Liss; 1991:101-108.
50. Gordon-Smith EC, Fairhead SM, Chipping PM, et al. Bone-marrow transplantation for severe aplastic anaemia using histocompatible unrelated volunteer donors. Br Med J. 1982;285:835-837.
51. Deeg HJ, Anasetti C, Petersdorf E, et al. Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors [letter]. Blood. 1994;83:3417-3418.
52. Gluckman E, Horowitz MM, Champlin RE, et al. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood. 1992;79:269-275.
53. Deeg HJ, Amylon MD, Harris RE, et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant. 2001;7:208-215.
54. Kojima S, Inaba J, Yoshimi A, et al. Unrelated donor marrow transplantation in children with severe aplastic anemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. Br J Haematol. 2001;114:706-711.
55. Vassiliou GS, Webb DKH, Pamphilon D, Knapper S, Veys PA. Improved outcome of alternative marrow donor bone marrow transplantation in children with severe aplastic anemia using a conditioning regimen containing low-dose total body irradiation, cyclophosphamide and Campath. Br J Haematol. 2001;114:701-705.
56. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92:3515-3520.